Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

expansion stage of the trial, which will enroll a total of 46 advanced breast cancer patients overall.
  • Reported that in a Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) patients with locally advanced or metastatic disease, 11 of 17, or almost 65% of evaluable patients in the initial cohort, achieved an objective tumor response according to RECIST criteria. These early results, which exceeded the pre-specified endpoint needed to expand the trial, compare very favorably with historical data with chemotherapy alone and are especially encouraging in this hard-to-treat cancer. Patient enrollment and dosing are continuing in the expansion stage of the trial, which will enroll a total of 49 NSCLC patients overall.
  • Completed patient enrollment in a Phase I trial evaluating bavituximab as monotherapy in patients with advanced refractory cancers. At the 2009 ASCO Annual Meeting, study researchers reported that bavituximab had demonstrated a predictable pharmacokinetic profile and acceptable safety, and that a maximum tolerated dose was not reached, even at the highest planned dose level.
  • Announced that the ASCO Research Foundation awarded one of its 2009 Career Development Awards to a researcher at the University of Texas Southwestern Medical Center for a study of the biologic effects of bavituximab and chemotherapy in patients with advanced lung cancer.
  • Presented data from two studies at the AACR 2009 Annual Meeting providing further confirmation of the unique immunomodulatory mechanisms contributing to the anti-tumor activity of Peregrine's anti-PS antibody platform.
  • Bavituximab Anti-Viral Program

    The company continued to advance the bavituximab anti-viral program:

    • Received major validation of the broad anti-viral potential of the company's anti-PS antib
      '/>"/>

    SOURCE Peregrine Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine news :

    1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
    2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
    3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
    4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
    5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
    6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
    7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
    8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
    9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
    11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2014)... By Dennis Thompson ... -- An experimental Ebola drug previously given to two American ... the deadly virus in laboratory tests, researchers report. The ... it, even if they didn,t get the medication until five ... cases of Ebola who were days or even hours away ...
    (Date:9/1/2014)... As well as having completed the Non ... counselor certification in Louisiana. , "I have ... program as well as the Counselor training program ... and professionally. I am not only dedicated to ... do so. As a Non Violent Crisis Intervention ...
    (Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... to store, retrieve, organize and analyze biological and ... comprises of the activity of developing software tools ... is not to be confused with biological computation. ... the better understanding of biology can its related ...
    (Date:9/1/2014)... 01, 2014 Registration is now open for ... and 1-Mile Race to be held on Sunday, September 21, ... Yard at Harmon Meadow in Secaucus, New Jersey. All proceeds ... national nonprofit dedicated to restoring a sense of self, restoring ... and our military families. , General registration is $30 with ...
    (Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
    Breaking Medicine News(10 mins):Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
    ... of jaundice were detected here today even as health ... be suffering from the disease. // ,Officials ... found four persons including two children were suffering from ... civil surgeon visited the area as doctors collected blood ...
    ... doctors in Toronto are desperately trying to reattach the foot of ... freak accident that involved his father // riding over him on ... boys father had been riding a lawn mower when the boy ... father had put the mower into reverse and accidentally ran over ...
    ... women will have a vaccine to protect themselves from cervical ... 'Gardasil' produced by American pharmaceutical giant Merck. // ... the vaccine, Gardasil, for use in girls and women ages ... an early release of products with potential to provide significant ...
    ... soon launch a Rs 350 crore Integrated Disease Surveillance ... throughout the country. // ,Union Health minister ... Bank-funded project would be able to create a veritable ... cardio-vascular diseases and even road accidents., ,'This will ...
    ... Recent research has revealed that taking antibiotics for three days ... is equally effective in the treatment of common pneumonia // ... to curb the rising problem of antibiotic-resistant bacteria, ... diseases at the Academic Medical Center, in Amsterdam said,’The question ...
    ... the death toll was so overwhelming that steam shovels were ... //memorial services, trains commandeered to transport dead soldiers and priests ... ,With the threat of another flu pandemic looming in the ... providers making preparations for it mortuary specialists are once more ...
    Cached Medicine News:Health News:Pneumonia Effectively Treated with Short-Term Antibiotic Course 2Health News:What to do with the Dead if a Flu Outbreak Happens? 2
    (Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
    (Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
    (Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Research and Development Trend Forecast of Pharmaceutical ... offering. Research and Development Trend Forecast ... , 2014-2018 mainly analyzes China,s ... status, supply & demand, competition landscape, and business performance ...
    Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
    ... that it received $2.5 million from AstraZeneca AB pursuant to the September 2009 amendment of the exclusive ... indications. , ... , ... ...
    ... , ... ... - Spasticity Affects a Significant Number of Post-Stroke Patients,[1],[2],[3] and Many are not Adequately Treated by Standard Therapy [4] , ... , , ...
    Cached Medicine Technology:Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 3First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 4First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 5First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 6First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 7First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 8First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 9
    Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
    Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
    McPherson curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 85 mm....
    McPherson straight tying forceps made of titanium, straight shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 87 mm....
    Medicine Products: